Abstract
The seven-spanning transmembrane G-protein coupled receptor CXCR4, which specifically binds to the chemokine CXCL12, is expressed on many cell types, including various types of tumour cells. CXCR4 plays a crucial role in organ-specific metastasis, directing migration of malignant cells expressing this receptor toward microenvironments where the cognate ligand is secreted. CXCL12 has a direct growth and survival-promoting effect for various cancer cells and enhances moreover tumour angiogenesis by recruiting endothelial progenitor cells to tumours. Drugs which modulate the CXCL12/CXCR4 axis are therefore promising candidates in anti-cancer therapies. CXCR4 is also a coreceptor for human immunodeficiency virus type 1 (HIV-1) X4 virus and, as such, plays an important role in virus entry into target cells. Hence, antiviral agents that bind to CXCR4 are expected to inhibit HIV-1 entry. Here we review the structure, mechanism of action and biological activity of the main CXCR4 antagonists (peptide inhibitors, non-peptide antagonists, neutralizing antibodies, modified analogues of CXCL12) and agonists (CXCL12 peptide analogues) and discuss the CXCL12/CXCR4 axis as an important target in development of anti-tumoral and anti-HIV-1 therapies.
Keywords: CXCR4, CXCL12, antagonist, agonist, analogue, cancer, HIV-1, hematopoietic progenitor mobilization, cognate ligand, angiogenesis, human immunodeficiency virus type 1, peptide inhibitors,, chemokine receptors, G-protein coupled receptor (GPCR), bone marrow, lymph nodes, lung, brain, liver, peptide, Tachypleus tridentatus, Limulus polyphemus, TZ14004, TN14003, TC14012, 4F-benzoyl-TN14003, T-140-Based Cyclic Pentapeptides, Linear T140-Based Oligopeptides, tripeptide mimetics, p-fluorobenzoylated tripeptide mimetics, AMD3100, AMD3100-Based Non-Cyclam Compounds, Dipicolylamine zinc(II)-Based Compounds, HSEFFR-CPC-RFFESH, aberrant hematopoiesi, homodimerization, Epstein-Barr virus-encoded
Current Medicinal Chemistry
Title: The CXCL12/CXCR4 Axis as a Therapeutic Target in Cancer and HIV-1 Infection
Volume: 18 Issue: 4
Author(s): L. Patrussi and C. T. Baldari
Affiliation:
Keywords: CXCR4, CXCL12, antagonist, agonist, analogue, cancer, HIV-1, hematopoietic progenitor mobilization, cognate ligand, angiogenesis, human immunodeficiency virus type 1, peptide inhibitors,, chemokine receptors, G-protein coupled receptor (GPCR), bone marrow, lymph nodes, lung, brain, liver, peptide, Tachypleus tridentatus, Limulus polyphemus, TZ14004, TN14003, TC14012, 4F-benzoyl-TN14003, T-140-Based Cyclic Pentapeptides, Linear T140-Based Oligopeptides, tripeptide mimetics, p-fluorobenzoylated tripeptide mimetics, AMD3100, AMD3100-Based Non-Cyclam Compounds, Dipicolylamine zinc(II)-Based Compounds, HSEFFR-CPC-RFFESH, aberrant hematopoiesi, homodimerization, Epstein-Barr virus-encoded
Abstract: The seven-spanning transmembrane G-protein coupled receptor CXCR4, which specifically binds to the chemokine CXCL12, is expressed on many cell types, including various types of tumour cells. CXCR4 plays a crucial role in organ-specific metastasis, directing migration of malignant cells expressing this receptor toward microenvironments where the cognate ligand is secreted. CXCL12 has a direct growth and survival-promoting effect for various cancer cells and enhances moreover tumour angiogenesis by recruiting endothelial progenitor cells to tumours. Drugs which modulate the CXCL12/CXCR4 axis are therefore promising candidates in anti-cancer therapies. CXCR4 is also a coreceptor for human immunodeficiency virus type 1 (HIV-1) X4 virus and, as such, plays an important role in virus entry into target cells. Hence, antiviral agents that bind to CXCR4 are expected to inhibit HIV-1 entry. Here we review the structure, mechanism of action and biological activity of the main CXCR4 antagonists (peptide inhibitors, non-peptide antagonists, neutralizing antibodies, modified analogues of CXCL12) and agonists (CXCL12 peptide analogues) and discuss the CXCL12/CXCR4 axis as an important target in development of anti-tumoral and anti-HIV-1 therapies.
Export Options
About this article
Cite this article as:
Patrussi L. and T. Baldari C., The CXCL12/CXCR4 Axis as a Therapeutic Target in Cancer and HIV-1 Infection, Current Medicinal Chemistry 2011; 18 (4) . https://dx.doi.org/10.2174/092986711794480159
DOI https://dx.doi.org/10.2174/092986711794480159 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advanced Management Options for Endometriosis
Current Women`s Health Reviews Lifelong Endocrine Fluctuations and Related Cognitive Disorders
Current Pharmaceutical Design The mTOR Pathway: A New Target in Cancer Therapy
Current Cancer Drug Targets Olive Oil and Cancer Risk: an Update of Epidemiological Findings through 2010
Current Pharmaceutical Design Prothymosin α and its C-Terminal Immunoreactive Decapeptide Show No Evidence of Acute Toxicity: A Preliminary <i>In Silico</i>, <i>In Vitro</i> and <i>In Vivo</i> Investigation
Current Medicinal Chemistry Dietary Phytochemicals in Chemoprevention of Cancer: An Update
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Detrimental Effect of Smoking on Female Fertility and IVF Success
Current Women`s Health Reviews GIST and Breast Cancer: 3 Case Reports and a Review of the Literature
Current Cancer Therapy Reviews Downstream Carcinogenesis Signaling Pathways by Green Tea Polyphenols: A Translational Perspective of Chemoprevention and Treatment for Cancers
Current Drug Metabolism DMBA- Induced Breast Cancer: A Hormonal Camouflage
Current Cancer Therapy Reviews Anticancer Mammalian Target of Rapamycin (mTOR) Signaling Pathway Inhibitors: Current Status, Challenges and Future Prospects in Management of Epilepsy
CNS & Neurological Disorders - Drug Targets Low Grade Inflammation as a Common Pathogenetic Denominator in Age-Related Diseases: Novel Drug Targets for Anti-Ageing Strategies and Successful Ageing Achievement
Current Pharmaceutical Design Angiogenesis and Anti-angiogenic Therapies in Epithelial Ovarian Cancer
Current Angiogenesis (Discontinued) Natural Products and Cancer Stem Cells
Current Pharmaceutical Design CD26/Dipeptidyl Peptidase IV as a Novel Therapeutic Target for Cancer and Immune Disorders
Mini-Reviews in Medicinal Chemistry Cellular Communication in Bone Homeostasis and the Related Anti-osteoporotic Drug Development
Current Medicinal Chemistry Polycystic Ovary Syndrome: A Contemporary Clinical Approach
Current Pharmaceutical Design Structural and Functional Diversity of Estrogen Receptor Ligands
Current Topics in Medicinal Chemistry Novel Drug-Induced Pulmonary Complications in Cancer Patients You Can Save Life!
Current Respiratory Medicine Reviews The Role of Epigenetics in Drug Resistance in Cancer
Epigenetic Diagnosis & Therapy (Discontinued)